1.The Efficacy of a Monocular Drug Trial in Normal-Tension Glaucoma.
Jong Yeon LEE ; Young Hoon HWANG ; Yong Yeon KIM
Korean Journal of Ophthalmology 2012;26(1):26-31
PURPOSE: To evaluate the efficacy of a monocular drug trial in eyes with normal-tension glaucoma (NTG). METHODS: This prospective study enrolled 74 patients with NTG. The monocular drug trial was started using latanoprost 0.005% for one week. If the intraocular pressure (IOP) reduction was greater than 15%, the same medication was administered to both eyes for one month. The unadjusted change and adjusted change (the change in the treated eye minus the change in the contralateral eye) in IOP were evaluated, and the predictors of IOP response were analyzed by multivariate linear regression. RESULTS: Among the initial 74 patients, 31 (41.9%) were included; others were excluded because they did not meet the requisite conditions. The most significant predictors of IOP response in the initial eye and subsequent eye were the baseline IOPs in both eyes (beta = 0.907, 0.771, respectively). The adjusted change in IOP of the initial eye had greater association (beta = 0.589) with the IOP after monocular trial in the initial eye than that of unadjusted IOP change (beta = 0.279). The adjusted change in IOP also had greater predictability (beta = 0.348) for IOP after monocular trial in the subsequent eye than that of the unadjusted IOP change (beta = 0.090). CONCLUSIONS: Although the monocular trial in NTG patients had limited efficacy due to its stringent conditions, it was useful for evaluating the IOP response in the initial eye and for predicting the IOP response in the subsequent eye.
Adult
;
Aged
;
Aged, 80 and over
;
Antihypertensive Agents/*therapeutic use
;
Female
;
Humans
;
Intraocular Pressure/drug effects
;
Linear Models
;
Low Tension Glaucoma/*drug therapy
;
Male
;
Middle Aged
;
Prospective Studies
;
Prostaglandins F, Synthetic/*therapeutic use
;
Statistics, Nonparametric
;
Treatment Outcome
2.The Effect of Latanoprost on Intraocular Pressure during 12 Months of Treatment for Normal-tension Glaucoma.
Korean Journal of Ophthalmology 2005;19(4):297-301
PURPOSE: To evaluate the intraocular pressure (IOP) -lowering efficacy of latanoprost in normal-tension glaucoma (NTG). METHODS: One-hundred and seventeen eyes of 63 NTG patients treated with 0.005% latanoprost once a day were enrolled in this study. Of these, 85 eyes of 47 patients were treated for 12 months. Mean IOPs were analyzed, and the mean IOP reductions from the untreated baseline were assessed after two weeks and after 1, 3, 6, 9, and 12 months of treatment. RESULTS: The mean untreated baseline IOP was 15.0+/-2.7 mmHg. After two weeks of latanoprost treatment, the mean IOP reduction from the baseline value was 2.6+/-0.2 mmHg (17.3%, p< 0.05), and after 6 and 12 months, the reduction was 2.4+/-0.2 mmHg (16.0%, p< 0.05) and 2.4+/-0.2 mmHg (16.0%, p< 0.05), respectively. Patients with a baseline IOP of > or=15 mmHg achieved significantly higher IOP reductions than those with a baseline IOP of < 15 mmHg at all follow-ups (p< 0.05). CONCLUSIONS: Latanoprost was found to be well tolerated and to significantly reduce IOP in NTG patients.
Treatment Outcome
;
Time Factors
;
Retrospective Studies
;
Prostaglandins F, Synthetic/administration & dosage/*therapeutic use
;
Middle Aged
;
Male
;
Intraocular Pressure/*drug effects/physiology
;
Humans
;
Glaucoma, Open-Angle/*drug therapy/physiopathology
;
Follow-Up Studies
;
Female
;
Dose-Response Relationship, Drug
;
Antihypertensive Agents/administration & dosage/*therapeutic use
;
Aged, 80 and over
;
Aged
;
Adult
3.Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma.
Deepak MISHRA ; Bibhuti Prassan SINHA ; Mahendra Singh KUMAR
Korean Journal of Ophthalmology 2014;28(5):399-407
PURPOSE: To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and timolol in reducing intraocular pressure (IOP) in patients with primary open angle glaucoma. METHODS: This was a prospective study conducted at a tertiary-care centre. One hundred and forty patients with newly diagnosed primary open angle glaucoma were randomly assigned to treatment with latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%) or timolol gel (0.5%); 35 patients were assigned to each group. All patients were followed for 2, 6, and 12 weeks. The main outcome measure studied was the change in IOP at week 12 from the baseline values. Safety measures included recording of adverse events. RESULTS: The mean IOP reduction from baseline at week 12 was significantly more with bimatoprost (8.8 mmHg, 35.9%) than with latanoprost (7.3 mmHg, 29.9%), travoprost (7.6 mmHg, 30.8%) or timolol (6.7 mmHg, 26.6%) (ANOVA and Student's t-tests, p < 0.001). Among the prostaglandins studied, bimatoprost produced a maximum reduction in IOP (-2.71; 95% confidence interval [CI], -2.25 to -3.18) followed by travoprost (-1.27; 95% CI, -0.81 to -1.27) and latanoprost (-1.25; 95% CI, -0.79 to -1.71); these values were significant when compared to timolol at week 12 (Bonferroni test, p < 0.001). Latanoprost and travoprost were comparable in their ability to reduce IOP at each patient visit. Ocular adverse-events were found in almost equal proportion in patients treated with bimatoprost (41.3%) and travoprost (41.9%), with a higher incidence of conjunctival hyperemia (24.1%) seen in the bimatoprost group. Timolol produced a significant drop in heart rate (p < 0.001) at week 12 when compared to the baseline measurements. CONCLUSIONS: Bimatoprost showed greater efficacy when compared to the other prostaglandins, and timolol was the most efficacious at lowering the IOP. Conjunctional hyperemia was mainly seen with bimatoprost. However, the drug was tolerated well and found to be safe.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antihypertensive Agents/adverse effects/*therapeutic use
;
Bimatoprost/adverse effects/therapeutic use
;
Blood Pressure/drug effects
;
Female
;
Glaucoma, Open-Angle/*drug therapy/physiopathology
;
Heart Rate/drug effects
;
Humans
;
Intraocular Pressure/drug effects
;
Male
;
Middle Aged
;
Prostaglandins F, Synthetic/adverse effects/therapeutic use
;
Timolol/adverse effects/therapeutic use
;
Tonometry, Ocular
;
Travoprost/adverse effects/therapeutic use
;
Treatment Outcome
;
Visual Acuity/drug effects
;
Visual Field Tests
;
Visual Fields/drug effects